Evidence map›Paper›PMID 39805236›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2025

Subgroups varying in risk and density highlight the potential for stratified breast cancer screening.

Eugenio Gil Quessep, Danielle van der Waal, Jim Peters, Suzette Delaloge, Carla van Gils, Harry J de Koning, Mireille Broeders, Nicolien van Ravesteyn

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eugenio Gil QuessepDepartment of Public Health, Erasmus MC, Rotterdam, the Netherlands. Electronic address: e.gilquessep@erasmusmc.nl.
Danielle van der WaalDutch Expert Centre for Screening, Postbus 6873 6503 GJ, Nijmegen, the Netherlands.
Jim PetersIQ Health science department, Radboud University Medical Center, Postbus 9101, huispost 160 6500 HB, Nijmegen, the Netherlands.
Suzette DelalogeDepartment of Cancer Medicine, Gustave Roussy, 114 rue Edouard-Vaillant, Villejuif, Cedex 94 805, France.
Carla van GilsJulius Center for Health Sciences and Primary Care, University Medical Center, Utrecht University, Huispost nr. STR 6.131 P.O. Box 85500 3508, Utrecht, GA, the Netherlands.
Harry J de KoningDepartment of Public Health, Erasmus MC, Rotterdam, the Netherlands.
Mireille BroedersDutch Expert Centre for Screening, Postbus 6873 6503 GJ, Nijmegen, the Netherlands; IQ Health science department, Radboud University Medical Center, Postbus 9101, huispost 160 6500 HB, Nijmegen, the Netherlands.
Nicolien van RavesteynDepartment of Public Health, Erasmus MC, Rotterdam, the Netherlands.

Funding

Comparative Modeling of Precision Breast Cancer Control Across the Translational Continuum - SupplementU01CA253911 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI ALAGOZ, OGUZHAN, DE KONING, HARRY J · 2020 to 2025
$10.6M
NCI NIH HHS U01 CA253911
6 · The paper itself

Abstract

Most breast cancer screening programs rely only on demographic data without considering individual risk factors of the population, which might limit their effectiveness by over- and underscreening specific subgroups. Therefore, the aim of this study is to highlight health and economic disparities in outcomes from such a uniform screening strategy. With the microsimulation model MISCAN, we simulated outcomes of the Dutch screening program considering 16 subgroups varying by their 5-year breast cancer risk and breast density. All outcomes showed significant disparities across risk-density subgroups. Notably, women with extremely dense breasts showed a mortality reduction from the current screening of 16-17 % compared to 25-29 % in other groups. Absolute benefits (breast cancer deaths averted, and life-years gained) increased with risk and varied independently by density. The range of false-positive rates varied almost twofold across the span of subgroups and nearly a ninefold difference in the medical costs incurred with lifelong follow-up. These findings emphasize the potential for stratified screening strategies to improve equity in health outcomes and reduce the burden of breast cancer.

Indexed as

Breast DensityBreast NeoplasmsEarly Detection of CancerMammographyAdultAgedFemaleHumansMass ScreeningMiddle AgedNetherlandsRisk AssessmentRisk FactorsBreast densityBreast neoplasmsComputational modelingCost of illnessEarly detection of cancerMammographyNetherlandsPopulation healthRisk factors

Identifiers

PMID39805236
PMCPMC13067045

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.